Better Benefit-to-Risk Ratio for Anti-CGRP mAbs Than Current Migraine Preventive Medication

Retrieved on: 2021-04-19 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

Better Benefit-to-Risk Ratio for Anti-CGRP mAbs Than Current Migraine Preventive Medication. View article details on hiswai:

Excerpt

Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) exhibit a more favorable benefit-to-risk ratio than ...

Article found on: www.clinicalpainadvisor.com